Literature DB >> 4674081

Infectious antibody-reovirus complexes.

D O Huggett, J E Rodríguez, A P McKee.   

Abstract

Populations of reovirus type 1 could not be completely neutralized by exposure to specific antiviral serum. Aggregation of reovirions before or after exposure to neutralizing antibody was discarded as a possible explanation for the phenomenon observed. Anti-rabbit serum and equilibrium zonal density gradient centrifugation were used to show that the residual infectious fraction consisted of infectious antibody-virion complexes. Electron microscopy and equilibrium density gradient centrifugation of stock virus preparations were used to attempt to determine whether the infectious virus-antibody complexes resulted from the combination of antibody with virus particles which differed from neutralizable virions either morphologically or with regard to buoyant density. Although electron micrographs revealed the presence of three morphologically distinct classes of virus particles, density gradient centrifugation resulted in only one infectious peak. Density gradient centrifugation of virus exposed to antibody resulted in only one infectious peak which consisted of virus-antibody complexes.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4674081      PMCID: PMC419321          DOI: 10.1128/iai.6.6.996-1002.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Neutralization of viral infectivity: characterization of the virus-antibody complex, including association, dissociation, and host-cell interaction.

Authors:  B MANDEL
Journal:  Ann N Y Acad Sci       Date:  1960-01-13       Impact factor: 5.691

2.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus.

Authors:  R DULBECCO; M VOGT; A G STRICKLAND
Journal:  Virology       Date:  1956-04       Impact factor: 3.616

3.  Virus aggregation as the cause of the non-neutralizable persistent fraction.

Authors:  C Wallis; J L Melnick
Journal:  J Virol       Date:  1967-06       Impact factor: 5.103

4.  Morphological variants of coliphage P1.

Authors:  D H Walker; T F Anderson
Journal:  J Virol       Date:  1970-06       Impact factor: 5.103

5.  Neutralization of sensitized lactic dehydrogenase virus by anti-gammglobulin.

Authors:  A L Notkins; M Mage; W K Ashe; S Mahar
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

6.  Role of adenovirus antigens in the induction of virus neutralizing antibody.

Authors:  L Kjellén; H G Pereira
Journal:  J Gen Virol       Date:  1968-01       Impact factor: 3.891

7.  Preparation and properties of the internal capsid components of reovirus.

Authors:  H D Mayor; L E Jordan
Journal:  J Gen Virol       Date:  1968-09       Impact factor: 3.891

8.  The molecular weight of a rabbit antibody.

Authors:  M D Memet-Bratley
Journal:  Biochim Biophys Acta       Date:  1970-04-28

9.  Correlation of infectivity and hemagglutinins of reoviruses.

Authors:  R Engler; M T Fouad
Journal:  Proc Soc Exp Biol Med       Date:  1968-12

10.  STUDIES ON PERSISTENT INFECTIONS OF TISSUE CULTURES. V. THE INITIAL STAGES OF INFECTION OF L(MCN) CELLS BY NEWCASTLE DISEASE VIRUS.

Authors:  J E RODRIGUEZ; W HENLE
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

View more
  4 in total

1.  Enhancement by diethylamineothyl-dextran of the plaque-forming activity of foot-and-mouth disease virus-antibody complexes in pig kidney IB-RS-2 cells.

Authors:  J C Booth
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

2.  Dose-response relationships in a microneutralization test for foot-and-mouth disease viruses.

Authors:  J C Booth; M M Rweyemamu; T W Pay
Journal:  J Hyg (Lond)       Date:  1978-02

3.  Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity.

Authors:  W A Volk; R M Synder; D C Benjamin; R R Wagner
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

4.  Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.

Authors:  Victoria Roulstone; David Mansfield; Robert J Harris; Katie Twigger; Christine White; Johann de Bono; James Spicer; Sophia N Karagiannis; Richard Vile; Hardev Pandha; Alan Melcher; Kevin Harrington
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.